NVSNovartis PharmaceuticalsRunning, no new patients
Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation
Advanced HER2+Breast Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 19 (final count)
- Started
- Jul 16, 2020
- Main results expected
- Feb 26, 2027
- Fully finished
- Feb 26, 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Part 1: Incidence of dose limiting toxicities (DLTs) for each dose level
Measured over: 6 weeks
Part 2: Progression Free Survival (PFS)
Measured over: Up to approximately 38 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT04208178 · record last updated 2026-09-18 · checked 2026-11-09 15:47 UTC